| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/07/2013 | WO2013033396A2 Fap-activated proteasome inhibitors for treating solid tumors |
| 03/07/2013 | WO2013033377A1 Aldh-2 inhibitors in the treatment of addiction |
| 03/07/2013 | WO2013033370A1 Prevention and treatment of thrombosis in medically ill patients |
| 03/07/2013 | WO2013033366A2 Methods and compositions for promoting glucose homeostasis |
| 03/07/2013 | WO2013033345A1 Immunomodulators and immunomodulator conjugates |
| 03/07/2013 | WO2013033283A1 Improving systemic glucose tolerance in type-2 diabetes |
| 03/07/2013 | WO2013033269A1 Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
| 03/07/2013 | WO2013033268A2 Bivalent bromodomain ligands, and methods of using same |
| 03/07/2013 | WO2013033250A1 Certain chemical entities, compositions, and methods |
| 03/07/2013 | WO2013033246A2 Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof |
| 03/07/2013 | WO2013033240A1 Antibacterial compounds and methods for use |
| 03/07/2013 | WO2013033228A1 Antibacterial compounds and methods for use |
| 03/07/2013 | WO2013033203A1 Compounds and compositions as c-kit kinase inhibitors |
| 03/07/2013 | WO2013033194A1 Levothyroxine formulations |
| 03/07/2013 | WO2013033178A1 Methods and compositions for treating nephrogenic diabetes insipidus |
| 03/07/2013 | WO2013033176A1 Decitabine derivative formulations |
| 03/07/2013 | WO2013033167A1 Compounds and compositions as c-kit kinase inhibitors |
| 03/07/2013 | WO2013033155A1 Methods and compositions for reducing serum levels of immunoglobulin e (ige) |
| 03/07/2013 | WO2013033133A1 Use of organic compound for the treatment of noonan syndrome |
| 03/07/2013 | WO2013033116A1 Compounds and compositions as c-kit kinase inhibitors |
| 03/07/2013 | WO2013033085A1 Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| 03/07/2013 | WO2013033070A1 COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS |
| 03/07/2013 | WO2013033061A1 Fused bicyclic diamine derivatives as hiv attachment inhibitors |
| 03/07/2013 | WO2013033059A1 Spiro bicyclic diamine derivatives as hiv attachment inhibitors |
| 03/07/2013 | WO2013033041A1 Platinum anticancer agents |
| 03/07/2013 | WO2013033037A2 Novel antiprion compounds |
| 03/07/2013 | WO2013033004A2 Metalloenzyme inhibitor compounds |
| 03/07/2013 | WO2013032960A2 Vitamin d receptor - coregulator inhibitors |
| 03/07/2013 | WO2013032951A1 Certain chemical entities, compositions, and methods |
| 03/07/2013 | WO2013032939A1 Bicyclic agonists of gpr131 and uses thereof |
| 03/07/2013 | WO2013032934A1 Compositions and methods thereof for oral administration of drugs |
| 03/07/2013 | WO2013032907A1 Compounds and methods for the treatment of cancer stem cells |
| 03/07/2013 | WO2013032893A1 The use of prolyl hydroxylase inhibitors as a radioprotective drug for the lower gastrointestinal tract |
| 03/07/2013 | WO2013032846A1 2-METHYLENE-19,23,24-TRINOR-1α-HYDROXYVITAMIN D3 |
| 03/07/2013 | WO2013032804A1 (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS |
| 03/07/2013 | WO2013032797A2 Oxetane 3,3-dicarboxamide compounds and methods of making and using same |
| 03/07/2013 | WO2013032744A2 Composition and use of a formulation to increase the ratio of gastrointestinal microbiota in phylum bacteriodites to microbiota of firmuctes phylum |
| 03/07/2013 | WO2013032674A1 Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
| 03/07/2013 | WO2013032643A2 Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells |
| 03/07/2013 | WO2013032591A1 Heterocyclic compounds and uses thereof |
| 03/07/2013 | WO2013032527A1 Llp2a-bisphosphonate conjugates for osteoporosis treatment |
| 03/07/2013 | WO2013032522A1 Pyrimidine carboxamide derivatives |
| 03/07/2013 | WO2013032351A1 Treatments involving eslicarbazepine acetate or eslicarbazepine |
| 03/07/2013 | WO2013032310A1 Fast-dissolving megestrol tablet and method for preparing same |
| 03/07/2013 | WO2013032231A2 Pharmaceutical anti-angiogenic composition including a microrna-382 inhibitor |
| 03/07/2013 | WO2013032230A2 Pharmaceutical angiogenic composition including a microrna-382 activator |
| 03/07/2013 | WO2013032201A2 Material for preventing adhesion, and method for preventing adhesion |
| 03/07/2013 | WO2013032185A1 Extended release preparation containing pregabalin |
| 03/07/2013 | WO2013032184A2 Composition comprising pyrazino-triazine derivatives |
| 03/07/2013 | WO2013032158A2 Method for inducing stem-cells to differentiate into muscle cells |
| 03/07/2013 | WO2013032096A1 Capric acid having inhibiting effect on osteoclast formation and pharmaceutical composition containing same |
| 03/07/2013 | WO2013032087A1 Pharmaceutical composition including c3g or mulberry extracts containing c3g for preventing or treating diabetic impotence |
| 03/07/2013 | WO2013032028A1 New compound material, medicine containing same, and cancer treatment method using same |
| 03/07/2013 | WO2013031992A1 Adhesive patch |
| 03/07/2013 | WO2013031935A1 Stable pharmaceutical composition |
| 03/07/2013 | WO2013031931A1 Chemokine receptor activity regulator |
| 03/07/2013 | WO2013031930A1 Imine derivative |
| 03/07/2013 | WO2013031922A1 Pyrazole compound and use thereof for medical purposes |
| 03/07/2013 | WO2013031833A1 Skin introduction system and lightening agent combining cell introduction peptide and skin introduction accelerator |
| 03/07/2013 | WO2013031831A1 Method for improving therapy for autoimmune diseases such as rheumatoid arthritis |
| 03/07/2013 | WO2013031729A1 Prophylactic/therapeutic agent for cardiovascular complications of diabetes |
| 03/07/2013 | WO2013031704A1 Heptamer-type small guide nucleic acid capable of inducing apoptosis of human leukemia cell |
| 03/07/2013 | WO2013031694A1 Amine compound and salt thereof |
| 03/07/2013 | WO2013031620A1 Osteogenesis promoter and use thereof |
| 03/07/2013 | WO2013031239A1 Novel mangromycin compound and production method therefor |
| 03/07/2013 | WO2013030803A1 Choline salt of an anti - inflammatory substituted cyclobutenedione compound |
| 03/07/2013 | WO2013030802A1 Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| 03/07/2013 | WO2013030789A1 Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor |
| 03/07/2013 | WO2013030768A1 Method and composition for treating lice infestation |
| 03/07/2013 | WO2013030750A1 Antiviral compounds |
| 03/07/2013 | WO2013030735A1 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections |
| 03/07/2013 | WO2013030733A1 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections |
| 03/07/2013 | WO2013030726A1 Programmed drug delivery |
| 03/07/2013 | WO2013030725A1 Methods for treating cardiovascular disorders |
| 03/07/2013 | WO2013030722A1 Crystalline lurasidone hydrochloride |
| 03/07/2013 | WO2013030713A1 Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds |
| 03/07/2013 | WO2013030692A1 Compositions and methods for the treatment of chronic pain |
| 03/07/2013 | WO2013030669A2 Treatment of inflammatory disease or disorder and compositions therefor |
| 03/07/2013 | WO2013030665A1 Pyrimidines as sodium channel blockers |
| 03/07/2013 | WO2013030602A1 Solid extended release composition for oral administration comprising substantially amorphous capecitabine |
| 03/07/2013 | WO2013030512A1 Use of compositions having a low polyamine content in the prevention or treatment of adverse effects linked to cancer treatment |
| 03/07/2013 | WO2013030459A1 Lipid composition for the prevention or treatment of skin problems |
| 03/07/2013 | WO2013030374A1 Novel crystal form |
| 03/07/2013 | WO2013030368A1 Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone |
| 03/07/2013 | WO2013030367A1 Biphenylcarboxamides as rock kinase inhibitors |
| 03/07/2013 | WO2013030366A1 Novel soft rock inhibitors |
| 03/07/2013 | WO2013030365A1 Novel rock kinase inhibitors |
| 03/07/2013 | WO2013030362A1 Modulators of mir-323-3p for the prevention or treatment of rheumatoid arthritis |
| 03/07/2013 | WO2013030358A1 Glycine b antagonists |
| 03/07/2013 | WO2013030348A1 Oral formulations containing hyaluronic acid for sustained drug release |
| 03/07/2013 | WO2013030288A1 Substituted annellated pyrimidine and the use thereof |
| 03/07/2013 | WO2013030267A1 Multi-layered release formulation |
| 03/07/2013 | WO2013030218A1 Selective and reversible inhibitors of ubiquitin specific protease 7 |
| 03/07/2013 | WO2013030216A1 Novel soft rock inhibitors |
| 03/07/2013 | WO2013030205A1 Parp inhibitors |
| 03/07/2013 | WO2013030177A1 Abuse resistant tablet comprising oxycodone and paracetamol |
| 03/07/2013 | WO2013030160A1 Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| 03/07/2013 | WO2013030150A1 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines |
| 03/07/2013 | WO2013030138A1 Pyrrolopyrazine kinase inhibitors |
| 03/07/2013 | WO2013030129A1 Transdermal therapeutic system for 5-aminolevulinic acid hydrochloride |